• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Kyverna Therapeutics Inc.

    3/27/25 4:53:22 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYTX alert in real time by email
    S-8 1 s-8_evergreen_mar_2025.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 27, 2025

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Kyverna Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

    Delaware

    83-1365411

    (State or other jurisdiction of incorporation or organization)

    (I.R.S. Employer Identification No.)

    5980 Horton St., STE 550

    Emeryville, CA 94608

    (Address of Principal Executive Offices) (Zip Code)

    Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan

    Kyverna Therapeutics, Inc. 2024 Employee Stock Purchase Plan

    (Full title of the plans)

    Warner Biddle

    Chief Executive Officer

    Kyverna Therapeutics, Inc.

    5980 Horton St., STE 550

    Emeryville, CA 94608

    (510) 925-2492

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Jeffrey T. Hartlin

    Samantha H. Eldredge

    Paul Hastings LLP

    1117 S. California Avenue

    Palo Alto, California 94304
    (650) 320-1800

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    REGISTRATION OF ADDITIONAL SECURITIES

    Kyverna Therapeutics, Inc. (the “Registrant”) has prepared this Registration Statement on Form S-8 (the “Registration Statement”) in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), to register (i) 2,160,745 additional shares of common stock, $0.00001 par value per share (“Common Stock”), of the Registrant issuable pursuant to the Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) and (ii) 422,000 additional shares of Common Stock issuable pursuant to the Kyverna Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the “2024 ESPP”). The Registrant’s stockholders have previously approved the 2024 Plan and the 2024 ESPP, including the shares of Common Stock available for issuance pursuant thereto.

    Pursuant to the Registration Statement on Form S-8 (File No. 333-276952) filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on February 8, 2024 (the “Prior Registration Statement”), the Registrant previously registered an aggregate of 4,215,000 shares of Common Stock under the 2024 Plan and 422,000 shares of Common Stock under the 2024 ESPP.

    In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statement are hereby incorporated by reference.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

    The following documents filed by the Registrant with the Commission are hereby incorporated by reference into this Registration Statement:

     

    (a)

    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 27, 2025;

     

     

     

    (b)

    The Registrant’s Current Report on Form 8-K filed with the Commission on January 21, 2025; and

     

     

     

    (c)

    The description of the Registrant’s common stock set forth in the Registration Statement on Form 8-A filed with the Commission on February 5, 2024 (File No. 001-41947) pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendments or reports filed for the purpose of updating such description, including the description of the Registrant’s securities included as Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on March 26, 2024.

    All other reports and other documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part of this Registration Statement from the date of the filing of such reports and documents, except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions.

    For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide you with different information. You

     

     

     


     

    should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.

    You may contact the Registrant in writing or orally to request copies of the above-referenced filings, without charge (excluding exhibits to such documents unless such exhibits are specifically incorporated by reference into the information incorporated into this Registration Statement). Requests for such information should be directed to:

     

    Kyverna Therapeutics, Inc.

    5980 Horton St., STE 550

    Emeryville, CA 94608

    (510) 925-2492

    Attn: Chief Executive Officer

    ITEM 4. DESCRIPTION OF SECURITIES.

    Not applicable.

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.

    Not applicable.

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

    Section 145 of the General Corporation Law of the State of Delaware, or the DGCL, authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors and other corporate agents.

    The Registrant’s amended and restated certificate of incorporation and amended and restated bylaws contain provisions that limit the liability of the Registrant’s directors and officers for monetary damages to the fullest extent permitted by Delaware law. Consequently, the Registrant’s directors and officers will not be personally liable to the Registrant or the Registrant’s stockholders for monetary damages for any breach of fiduciary duties as directors or officers, except liability for the following:

    •
    any breach of their duty of loyalty to the Registrant or the Registrant’s stockholders;
    •
    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
    •
    with respect to directors, unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL;
    •
    with respect to officers, derivative claims brought on behalf of the Registrant; or
    •
    any transaction from which they derived an improper personal benefit.

    Any amendment to, or repeal of, these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to that amendment or repeal. If the DGCL is amended to provide for further limitations on the personal liability of directors or officers of corporations, then the personal liability of the Registrant’s directors and officers will be further limited to the greatest extent permitted by the DGCL.

    The Registrant’s amended and restated certificate of incorporation also provides that the Registrant will indemnify, to the fullest extent permitted by law, each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the Registrant, or is or was serving, or has agreed to serve, at the request of the Registrant, as a director, officer, incorporator, employee or agent of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity. In addition, the Registrant’s amended and restated certificate of incorporation provides that the Registrant must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding, subject to very limited exceptions.

     

     

     


     

    Further, the Registrant has entered into, and expects to continue to enter into, indemnification agreements with each of its directors and executive officers that may be broader than the specific indemnification provisions contained in the DGCL. These indemnification agreements require the Registrant, among other things, to indemnify its directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Registrant to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding, subject to certain exceptions. The Registrant believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.

    The limitation of liability and indemnification provisions that are included in the Registrant’s amended and restated certificate of incorporation, amended and restated bylaws and in indemnification agreements that the Registrant enters into with its directors and executive officers may discourage stockholders from bringing a lawsuit against its directors and executive officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against the Registrant’s directors and executive officers even though an action, if successful, might benefit the Registrant and other stockholders. Further, a stockholder’s investment may be adversely affected to the extent that the Registrant pays the costs of settlement and damage awards against directors and executive officers as required by these indemnification provisions. Except as may be disclosed in this Registration Statement or the reports or documents incorporated by reference herein, the Registrant is not aware of any pending litigation or proceeding involving any person who is or was one of its directors, officers, employees or other agents or is or was serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, for which indemnification is sought, and the Registrant is not aware of any threatened litigation that may result in claims for indemnification.

    The Registrant’s amended and restated bylaws provide that the Registrant may purchase and maintain insurance, at its expense, to protect itself and any person who is or was a director, officer, employee or agent of the Registrant or is or was serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Registrant would have the power to indemnity such person against such expense, liability or loss under the DGCL. The Registrant has obtained insurance under which, subject to the limitations of the insurance policies, coverage is provided to the Registrant’s directors and executive officers against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or executive officer, including claims relating to public securities matters, and to the Registrant with respect to payments that may be made by the Registrant to these directors and executive officers pursuant to the Registrant’s indemnification obligations or otherwise as a matter of law.

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.

    Not applicable.

    ITEM 8. EXHIBITS.

    Exhibit Number

    Description

    3.1

    Amended and Restated Certificate of Incorporation of Kyverna Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 12, 2024).

    3.2

    Amended and Restated Bylaws of Kyverna Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 12, 2024).

    4.1

    Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-276523), filed on January 16, 2024).

    5.1*

    Opinion of Paul Hastings LLP.

     

     

     


     

    10.1

    Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-8 (File No. 333-276952), filed on February 8, 2024).

     

     

     

    10.2

    Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan Form of Stock Option Agreement (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-276523), filed on February 1, 2024).

     10.3

     

    Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan Form of Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-276523), filed on February 6, 2024.

     

     

     

    10.4

    Kyverna Therapeutics, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-8 (File No. 333-276952), filed on February 8, 2024).

     

     

     

    23.1*

    Consent of BDO USA, P.C., Independent Registered Public Accounting Firm.

    23.2*

    Consent of Paul Hastings LLP (included in Exhibit 5.1).

    24.1*

    Power of Attorney is contained on the signature page.

    107*

    Filing Fee Table.

    * Filed herewith.

    ITEM 9. UNDERTAKINGS.

    (a) The Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

    Provided, however, that:

    (A) paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

     

     


     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee bonus plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


     

     

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on March 27, 2025.

     

    KYVERNA THERAPEUTICS, INC.

    By:

    /s/ Warner Biddle

    Name:

     Warner Biddle

    Title:

    Chief Executive Officer

    POWER OF ATTORNEY

    Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints Warner Biddle and Ryan Jones, and each or any one of them, as his or her true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    SIGNATURE

    TITLE

    DATE

    /s/ Warner Biddle

    Chief Executive Officer and Director

    March 27, 2025

    Warner Biddle

    (Principal Executive Officer)

    /s/ Ryan Jones

    Chief Financial Officer

    March 27, 2025

    Ryan Jones

    (Principal Financial and Accounting Officer)

    /s/ Ian Clark

    Chairperson of the Board

    March 27, 2025

    Ian Clark

     

    /s/ Mert Aktar

    Director

    March 27, 2025

    Mert Aktar

    /s/ Fred E. Cohen, M.D., D. Phil.

    Director

    March 27, 2025

    Fred E. Cohen, M.D., D. Phil.

    /s/ Steve Liapis, Ph.D.

    Director

    March 27, 2025

    Steve Liapis, Ph.D.

     

     

    /s/ Christi Shaw

    Director

    March 27, 2025

    Christi Shaw

     

     

    /s/ Beth Seidenberg, M.D.

    Director

    March 27, 2025

    Beth Seidenberg, M.D.

     

     

    /s/ Daniel Spiegelman

    Director

    March 27, 2025

    Daniel Spiegelman

     

     

     

     

     

     


    Get the next $KYTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KYTX

    DatePrice TargetRatingAnalyst
    10/10/2024$13.00Buy
    UBS
    10/9/2024$16.00Buy
    Rodman & Renshaw
    7/3/2024$8.00Neutral
    H.C. Wainwright
    3/4/2024$40.00Overweight
    Morgan Stanley
    3/4/2024$39.00Overweight
    JP Morgan
    3/4/2024$44.00Overweight
    Wells Fargo
    3/4/2024$48.00Outperform
    Leerink Partners
    More analyst ratings

    $KYTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Kyverna Therapeutics Inc.

      10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)

      5/13/25 4:08:40 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)

      5/13/25 4:03:44 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Kyverna Therapeutics Inc.

      EFFECT - Kyverna Therapeutics, Inc. (0001994702) (Filer)

      4/16/25 12:15:18 AM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

      Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA) filing now anticipated in 1H 2026  Advancing into registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) following successful end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA); Phase 2 MG data anticipated in 2H 2025 Company to host KOL event in Q3 2025, spotlighting its accelerating neuroinflammation franchise  Strong financial position; cash runway into 2027 supports first BLA filing, MG Phase 3 trial and pre-launch activities  EMERYVILLE, Calif., May 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc.

      5/13/25 4:02:00 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration (FDA) on a registrational Phase 2 trial design for ongoing KYSA-8 trial in stiff person syndrome; 70% of study enrolled with topline data expected in 1H 2026; Biologics License Application (BLA) filing targeted for 2026   Clinical data in myasthenia gravis and lupus nephritis expected in 2H 2025   Strong balance sheet extends cash runway into 2027 through key clinical and regulatory catalysts EMERYVILLE, Calif., March 27, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company fo

      3/27/25 4:02:00 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

      EMERYVILLE, Calif., March 3, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET. A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on th

      3/3/25 4:05:00 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Kyverna Therapeutics with a new price target

      UBS initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $13.00

      10/10/24 7:37:04 AM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on Kyverna Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $16.00

      10/9/24 7:50:11 AM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Kyverna Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Kyverna Therapeutics with a rating of Neutral and set a new price target of $8.00

      7/3/24 7:31:52 AM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Biddle Warner Weston

      4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

      4/15/25 5:42:51 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Jones Ryan Alexander was granted 12,000 shares, increasing direct ownership by 27% to 55,950 units (SEC Form 4)

      4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

      4/15/25 5:42:36 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Technology Officer Walker Karen Marie was granted 13,000 shares, increasing direct ownership by 135% to 22,636 units (SEC Form 4)

      4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

      4/15/25 5:40:15 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

      Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of growth EMERYVILLE, Calif., Jan. 21, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of Naji Gehchan, M.D., MBA, to Chief Medical and Development Officer, where he will lead the Company's research, clinical development, and medical affairs functions. Dr. Gehchan brings 20 years of U.S. and international experience across multiple

      1/21/25 4:05:00 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors

      SANTA CRUZ, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today the appointment of Abbas Kazimi and Mert Aktar to its Board of Directors. "We are honored to welcome Abbas and Mert to our Board of Directors," said Cameron Pye, Ph.D., CEO and Co-Founder of Unnatural Products. "Abbas has an exceptional history of advancing groundbreaking therapies and forging impactful partnerships, and Mert's vast experience in leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms will be instrumental as we a

      1/8/25 8:00:00 AM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth

      Key Leadership Appointments Bring New Skills and Capabilities to Organization EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior Vice President of Corporate Affairs, Communications and Investor Relations.  "I'm pleased to welcome three industry leaders to our Kyverna team," sai

      12/13/24 4:05:00 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYTX
    Financials

    Live finance-specific insights

    See more
    • Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

      Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a conference call on April 16 to review recent named-patient experience in patients suffering from multiple sclerosis and myasthenia gravis EMERYVILLE, Calif., April 11, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today its attendance at the 2024 annual meeting of the American Academy of Neurology to be held in Denver, Colorado, starting

      4/11/24 5:01:00 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Kyverna Therapeutics Inc.

      SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)

      11/12/24 7:23:31 AM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Kyverna Therapeutics Inc.

      SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)

      10/10/24 12:36:27 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Kyverna Therapeutics Inc.

      SC 13D - Kyverna Therapeutics, Inc. (0001994702) (Subject)

      5/3/24 5:57:02 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care